About Daniel A Kracov

Daniel A Kracov s a partner at Arnold & Porter, where he chairs the life sciences industry practice. Daniel’s practice focuses on assisting pharmaceuticals, biotech, medical device and diagnostic companies – including global manufacturers, trade associations and emerging companies – in negotiating challenges relating to the development, approval and marketing of US Food and Drug Administration (FDA)-regulated products. In addition to day-to-day counselling on regulatory strategies and concerns, he regularly handles product- and compliance-related government and internal investigations, the development of global corporate compliance programmes, and due diligence in financings and M&A. Daniel has widely recognised experience in biomedical public policy matters, including Congressional investigations and advising on FDA-related legislation.